is allulose a glp-1 agonist the New Alternative to Weight Loss Drugs? | Ep 281 — Wits & Weights MD: You Can Get the
Description
We did a full webinar breaking down the topicmembers can access the recording on-demand , and download all the graphics from the session here
Guo (120) et al
JCI insight

Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction

5-12 However, in clinical trials, including SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide, participants were permitted to remain on a given dose for up to 4 additional weeks, as needed, to allow for the dissipation of any GI AEs

doi:10.6065/apem.2017.22.1.15 Doyle ME, Egan JM
